December 23, 2014European Heart Journal Acute Cardiovascular CareOpen Access

Among patients with negative contemporary troponin (TnI-Ultra < 99th percentile), elevated hsTnI (≥ 9 pg/ml) was associated with a higher risk of cardiovascular death or MI at one year (7.0% vs 3.8%; p<0.001, HR 2.05, 95% CI 1.23-3.41).

View Full Paper

Ask AI

Bookmark

Why the study?

Does a high-sensitivity troponin I assay improve prognostic risk stratification for cardiovascular death or MI compared to a contemporary sensitive assay in patients with non-ST elevation ACS?

Population

1807 patients with non-ST elevation acute coronary syndrome (NSTE-ACS)

Comparison

High-sensitivity troponin I assay measurement at… vs Current generation sensitive assay

Design

Cohort

Follow-up

one year

Authors

MBMarc P. Bonaca SMSabina A. Murphy PJPetr Jarolı́m

Discussion

Member takes

Overview

hsTnI may refine risk stratification in contemporary troponin-negative NSTE-ACS; hypothesis-generating and requires prospective validation.

Structured PICO

Does a high-sensitivity troponin I assay improve prognostic risk stratification for cardiovascular death or MI compared to a contemporary sensitive assay in patients with non-ST elevation ACS?

Population

1807 patients with non-ST elevation acute coronary syndrome (NSTE-ACS)

Intervention

High-sensitivity troponin I (hsTnI) assay (Erenna, Singulex) measurement at baseline

Comparator

Current generation sensitive assay (TnI-Ultra, Siemens)

Outcome

Adverse cardiovascular events (composite of cardiovascular death or myocardial infarction) at 30 days and one yearcomposite

Low-level cardiac troponin detected by a high-sensitivity assay identifies significant cardiovascular risk in NSTE-ACS patients who appear negative by contemporary assays.

Cite This Study

Bonaca et al. (2014) studied this question.

synapsesocial.com/papers/6a8246d881e7d96488ac9401 https://doi.org/10.1177/2048872614564081

View Full Paper

Ask AI

Bookmark

December 23, 2014European Heart Journal Acute Cardiovascular CareOpen Access

Among patients with negative contemporary troponin (TnI-Ultra < 99th percentile), elevated hsTnI (≥ 9 pg/ml) was associated with a higher risk of cardiovascular death or MI at one year (7.0% vs 3.8%; p<0.001, HR 2.05, 95% CI 1.23-3.41).

View Full Paper

Ask AI

Bookmark

Why the study?

Does a high-sensitivity troponin I assay improve prognostic risk stratification for cardiovascular death or MI compared to a contemporary sensitive assay in patients with non-ST elevation ACS?

Population

1807 patients with non-ST elevation acute coronary syndrome (NSTE-ACS)

Comparison

High-sensitivity troponin I assay measurement at… vs Current generation sensitive assay

Design

Cohort

Follow-up

one year

Authors

MBMarc P. Bonaca SMSabina A. Murphy PJPetr Jarolı́m

Discussion

Member takes

Overview

hsTnI may refine risk stratification in contemporary troponin-negative NSTE-ACS; hypothesis-generating and requires prospective validation.

Structured PICO

Does a high-sensitivity troponin I assay improve prognostic risk stratification for cardiovascular death or MI compared to a contemporary sensitive assay in patients with non-ST elevation ACS?

Population

1807 patients with non-ST elevation acute coronary syndrome (NSTE-ACS)

Intervention

High-sensitivity troponin I (hsTnI) assay (Erenna, Singulex) measurement at baseline

Comparator

Current generation sensitive assay (TnI-Ultra, Siemens)

Outcome

Adverse cardiovascular events (composite of cardiovascular death or myocardial infarction) at 30 days and one yearcomposite

Low-level cardiac troponin detected by a high-sensitivity assay identifies significant cardiovascular risk in NSTE-ACS patients who appear negative by contemporary assays.

Cite This Study

Bonaca et al. (2014) studied this question.

synapsesocial.com/papers/6a8246d881e7d96488ac9401 https://doi.org/10.1177/2048872614564081

View Full Paper

Ask AI

Bookmark